BOTULAX® 300u is a 300-unit purified Clostridium botulinum toxin type A formulation manufactured by Hugel, Inc. in South Korea and supplied as a lyophilized powder in a vial that requires reconstitution before use, per product labeling. By temporarily blocking acetylcholine release at the neuromuscular junction, it supports wrinkle reduction and, where locally authorized, therapeutic applications involving controlled neuromuscular blockade. Licensed professionals seeking to buy BOTULAX® 300u online for permitted clinical use may contact Medical Spa Rx’s professional support team for sourcing guidance and documentation support.
Product Specifications
- Active Substance: Purified Clostridium botulinum toxin type A
- Regulatory Status: Pharmaceutical product; regulatory status varies by jurisdiction
- Strength: 300 units (300u)
- Dosage Form: Sterile powder for reconstitution
- Manufacturer: Hugel, Inc.
- Package Content: 1 × 300u vial (powder)
- Country of Origin: South Korea
- Brand: BOTULAX®
- Therapeutic Applications: Wrinkle reduction and therapeutic applications according to clinical context
What Is BOTULAX® 300U?
BOTULAX® is a botulinum toxin type A brand manufactured by Hugel, Inc., a South Korean biopharmaceutical company with an established presence in medical aesthetics. [5] Regulatory filings identify the active ingredient as letibotulinumtoxinA, derived from the CBFC26 strain of Clostridium botulinum toxin type A, and registered with the Korean MFDS for specified presentations. [3][4]
The 300u vial designation offers licensed practitioners a higher unit content suited to multi-zone aesthetic protocols, larger treatment areas, or therapeutic applications requiring precise unit allocation across multiple injection sites. As with all botulinum toxin type A products, dosing decisions remain the responsibility of the treating practitioner, informed by patient anatomy, clinical indication, muscle characteristics, and applicable jurisdiction-specific guidance.
Supplied as a lyophilized powder, BOTULAX® 300u requires reconstitution before use, per product labeling. Preparation and administration are restricted to licensed healthcare professionals operating in compliance with applicable pharmaceutical and institutional protocols. Botulinum toxin type A is associated with softening dynamic facial wrinkles, which are lines that arise from repeated muscle contractions. [1]
Mechanism of Action
BOTULAX® 300u acts by inhibiting acetylcholine release at the presynaptic neuromuscular junction. Following injection, letibotulinumtoxinA enters cholinergic nerve terminals and cleaves SNAP-25, a SNARE protein essential for synaptic vesicle fusion, preventing the targeted muscle from contracting normally. [1] The result is localized, reversible muscle relaxation confined to the treatment area when proper injection technique is applied. This pharmacological mechanism supports wrinkle reduction in dynamic facial lines and underpins therapeutic applications where controlled neuromuscular blockade is clinically appropriate. [2]
The effect is temporary and reversible. Botulinum toxin type A, as a class, is generally associated with a clinical effect that begins within days of injection and lasts approximately 3–4 months, with variation depending on dose, treatment area, muscle mass, and individual patient response. [1] As nerve terminals regenerate and acetylcholine release is restored, muscle activity gradually returns, and maintenance treatment may be required to sustain clinical outcomes.
Therapeutic Applications & Indications
BOTULAX® 300u is used by licensed healthcare professionals in aesthetic and, where locally authorized, therapeutic contexts. In aesthetic practice, it is associated with the treatment of dynamic facial wrinkles caused by repetitive muscle contraction. Common treatment areas include:
- Glabellar lines (frown lines)
- Horizontal forehead lines
- Lateral canthal lines (crow’s feet)
- Bunny lines
- Chin dimpling
- Platysmal neck bands
For practitioners comparing botulinum toxins for multi-zone protocols, the 300u format supports efficient unit allocation across treatment areas within a single session. [1]
BOTULAX® (letibotulinumtoxinA) has been evaluated in Phase 3 clinical trials for both aesthetic and therapeutic indications. Evidence supports its study in post-stroke upper limb spasticity, providing a clinical basis for therapeutic use where temporary neuromuscular blockade offers functional benefit. [2] BOTULAX®-specific indications remain subject to country-specific labeling and local regulatory authorization; practitioners must verify currently approved indications in their jurisdiction before clinical use. [4]
Comprehensive patient assessment before treatment should cover facial anatomy, neuromuscular history, contraindication screening, current medications, prior botulinum toxin exposure, and treatment expectations. Informed consent should address onset, expected duration, potential adverse effects, reversibility, and maintenance considerations. Administration is restricted to licensed professionals with formal training in botulinum toxin procedures.
Reconstitution, Dilution & Administration Protocol
BOTULAX® 300u requires reconstitution before use, per product labeling. The lyophilized powder is combined with sterile saline, with the diluent volume selected to achieve the target unit concentration per milliliter. Specific dilution ratios, storage windows, and handling protocols are practitioner- and institution-dependent; no chart replaces the manufacturer’s current product guidance or formal clinical training. [3]
Dilution ratios are adjusted based on treatment area, muscle mass, injection depth, desired diffusion characteristics, and therapeutic objective. Practitioners who check for wholesale buying options should verify that procurement includes complete cold-chain documentation and storage history, as product integrity depends on unbroken temperature control from manufacture to use.
Safe preparation requires strict aseptic technique throughout: inspect the vial before use, confirm the diluent is appropriate for injection, disinfect the stopper before needle entry, and handle the reconstituted solution carefully to prevent foaming, contamination, or dosing inaccuracy.
Safety Considerations & Adverse Reactions
BOTULAX® 300u must be prepared and administered exclusively by licensed healthcare professionals. A Phase 3 clinical trial evaluating letibotulinumtoxinA in aesthetic use reported a safety profile consistent with the botulinum toxin type A class, with adverse events generally mild, localized, and transient. [1] Safe use depends on appropriate patient selection, accurate dilution, correct unit dosing, precise anatomical placement, and verified product handling throughout.
Common adverse reactions:
- Injection-site erythema, edema, and bruising
- Mild tenderness or discomfort
- Headache (occasional)
Less common adverse reactions:
- Facial asymmetry from inaccurate placement
- Unintended muscle weakness from excessive dosing or improper BOTULAX® 300u dilution
- Antibody formation (rare), which may reduce treatment response with repeated use
Contraindications include hypersensitivity to botulinum toxin or any formulation component, active infection at the injection site, known neuromuscular junction disorders such as myasthenia gravis, and pregnancy or lactation where local guidance restricts use. Any condition in which neuromuscular blockade poses additional clinical risk requires careful pre-treatment evaluation. When administered by trained practitioners applying appropriate preparation, dosing, and technique, BOTULAX® 300u may be used in suitable candidates within the scope of locally authorized indications.
Legal Status & Regulatory Requirements
BOTULAX® 300u is manufactured by Hugel, Inc. in South Korea and registered with the Korean MFDS as a biological drug product containing letibotulinumtoxinA, with indications specified for BOTULAX® presentations in Korea. [4][5] Practitioners who purchase botulinum toxins through professional channels should confirm that all products meet the applicable regulatory and documentation standards in their jurisdiction.
Regulatory status varies significantly by country. Licensed practitioners must confirm whether BOTULAX® 300u is authorized in their market before procurement or clinical use, as requirements differ with respect to product registration, importation authorization, prescription classification, storage mandates, and professional training standards.
Practitioners should independently verify applicable local regulations, confirm authorized sourcing channels, inspect package integrity and storage documentation, and review current product labeling before clinical use.
Where Can Licensed Professionals Buy BOTULAX® 300u Online?
When buying online, practitioners should require a certificate of analysis, verifiable LOT numbers, documented storage history, and confirmation of regulatory authorization for their target jurisdiction before finalizing any sourcing decision. Medical Spa Rx’s professional support team can provide guidance on documentation standards, supplier expectations, and professional account eligibility for practitioners looking to buy BOTULAX® through verified channels. Contact Medical Spa Rx’s professional support team directly to discuss procurement requirements, professional eligibility, and available documentation resources.
Citations and Resources
- Mueller DS, Prinz V, Adelglass J, et al. Efficacy and safety of letibotulinum toxin A in the treatment of glabellar lines: a randomized, double-blind, multicenter, placebo-controlled phase 3 study. Aesthetic Surgery Journal. 2022. https://pubmed.ncbi.nlm.nih.gov/35092418/
- Do KH, Chun MH, Paik NJ, et al. Safety and efficacy of letibotulinumtoxinA (BOTULAX®) in treatment of post stroke upper limb spasticity: a randomized, double blind, multi-center, phase III clinical trial. Clinical Rehabilitation. 2017. https://pubmed.ncbi.nlm.nih.gov/28118733/
- Bravo M, Vogel K, Sternfels W, Touchet N, Turegano M. Botulax and the US development. Dermatological Reviews. 2022. https://onlinelibrary.wiley.com/doi/abs/10.1002/der2.162
- Ministry of Food and Drug Safety (Korea). Biological Products: Hugel, Inc. 2016. https://www.mfds.go.kr/eng/brd/m_30/view.do?seq=69800
- Hugel, Inc. HUGEL. https://www.hugel-inc.com/
The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.